Reported Earlier, Tempus Announces Preliminary Q4 And FY25 Results With Revenue Of ~$367M In Q4 And ~$1.27B Full Year, Both Up ~83% YoY, And Record Total Contract Value Above $1.1B

Full Year 2025 Select, Preliminary, Unaudited Financial Results

• Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry)
• Diagnostics revenue of ~$955 million, representing ~111% growth year-over-year, driven by Oncology volume growth of ~26% and Hereditary volume growth of ~29%
• Data and applications revenue of ~$316 million, representing ~31% growth year-over-year, driven by ~38% growth in Insights (Data Licensing)

Fourth Quarter 2025 Select, Preliminary, Unaudited Financial Results

• Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year
• Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth of ~29% and Hereditary volume growth of ~23%
• Data and applications revenue of ~$100 million, representing ~25% year-over-year growth, with Insights growing ~68%, excluding the impact of the AstraZeneca warrant in Q4 of 2024.

Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38%

2025 Net revenue retention of ~126%